HA
SAGE icon

Harfst & Associates’s Sage Therapeutics SAGE Stock Holding History

Harfst & Associates’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-36
Closed -$2K – 186
2017
Q2 		$2K Hold
36
– – ﹤0.01% 225
2017
Q1 		$2K Buy
+36
New +$2.11K ﹤0.01% 276
2016
Q1 		– Sell
-36
Closed -$2K – 208
2015
Q4 		$2K Hold
36
– – ﹤0.01% 276
2015
Q3 		$2K Hold
36
– – ﹤0.01% 270
2015
Q2 		$3K Buy
+36
New +$2.31K ﹤0.01% 311

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Harfst & Associates's SAGE Position: Q3 2017 in Review

Harfst & Associates sold out of Sage Therapeutics (SAGE) in Q3 2017, closing a stake of 36 shares — an estimated $2K sold.

Harfst & Associates first reported a position in SAGE in Q2 2015 and held it in 5 quarters. The position peaked at $3K in Q2 2015. 174 funds tracked by Wall St. Rank hold SAGE as of Q3 2017.

  • Harfst & Associates reported no remaining Sage Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Harfst & Associates sold 36 Sage Therapeutics shares in Q3 2017, an estimated $2K.
  • Harfst & Associates first reported a position in Sage Therapeutics in Q2 2015 and held it in 5 quarters.
  • Harfst & Associates's Sage Therapeutics position peaked at $3K in Q2 2015.
  • 174 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2017.

Based on Harfst & Associates's 13F filing for Q3 2017, filed 7 Nov 2017.